Introduction.- Mechanisms of Cardiovascular Damage Induced by Traditional Chemotherapy.- Molecular Mechanisms of Cardiovascular Damage Induced by Anti HER2 Therapies.- Cardiovascular Damage Induced by Radiotherapy.- Cardiovascular Damage Induced by Anti-VEGF Therapy.- Cardiovascular Damage Induced by Anti-BCR-ABL TKIs.- Heart Failure and Left Ventricular Dysfunction.- Coronary Artery Disease.- Peripheral Artery Disease and Stroke.- Valvular Heart Disease.- Arterial Hypertension.- Atrial Fibrillation in Cancer.- Management of QT Prolongation Induced by Anti-cancer Drugs.- Pulmonary Hypertension Induced by Anti-cancer Drugs.- Venous Thromboembolism.- Early Detection of Cardiac Damage.- Diagnosis of Cardiac Damage: Role of Stress Echo.- Early Detection and Monitoring of Vascular Damage.- Prevention and Clinical Management of Cardiovascular Damage Induced by Anticancer Drugs: Need for Early Biomarkers and Cardio- and Vasculo-Protection in Personalized Therapy.- Cardiovascular Damage in Clinical Trials.
Antonio Russo, MD, PhD Full Professor of Medical Oncology Department of Surgical, Oncological and Oral Sciences (Di.Chir.On.S.) University of Palermo, Italy Director of Medical Oncology Section, University Hospital P. Giaccone Palermo, Italy
Giuseppina Novo, MD, PhD Associate Professor of Cardiology Biomedic Department of Internal Medicine and Specialities (DIBIMIS) University of Palermo, Italy Division of Cardiology, University Hospital P. Giaccone Palermo, Italy
Patrizio Lancellotti, MD, PhD University of Liège Hospital, GIGA Cardiovascular Sciences Department of Cardiology CHU Sart Tilman, Liège, Belgium Gruppo Villa Maria Care and Research, Anthea Hospital Bari, Italy
Antonio Giordano, MD PhD Director, Sbarro Institute for Cancer Research and Molecular Medicine and Center of Biotechnology College of Science and Technology Temple University PA 19122 USA
Fausto J. Pinto, MD, PhD, FESC, FACC, FSCAI, FASE Professor, University Hospital Santa Maria, CHLN University of Lisbon, Portugal Dept. of Cardiology Av Prof Egas Moniz Lisboa 1649-028 Portugal
This book is designed to provide a useful and comprehensive resource and state-of-the-art overview to readers about cardiovascular damage potentially induced by antineoplastic drugs. Thanks to more and more effective antineoplastic treatments, the survival of cancer patients is increasing at an exponential rate. However, the burden of related cardiovascular complications that affect morbidity and mortality are also on the rise. A new branch of cardiology, Cardio-Oncology, was developed to combat this trend. The aim of its conception is to prevent cardiovascular complications related to cancer therapy and to facilitate and avoid interruption of antineoplastic drugs due to the occurrence of cardiovascular damage. The text focuses on cardiovascular complications related to cancer treatment and reviews the pathophysiological mechanisms leading to cardiovascular toxicity related to various antineoplastic drugs. Diagnostic modalities for early diagnosis are also discussed, followed by preventive and therapeutic strategies.
Cardiovascular Complications in Cancer Therapy serves as a valuable resource for residents, fellow physicians, medical oncologists, cardiologists, and general practitioners and all those who take care of these patients.